(Q37847137)

24 August 2017

1 reference

title

Multisystem Langerhans cell histiocytosis in children: current treatment and future directions (English)

1 reference

Langerhans cell histiocytosis specific to childhood

24 August 2017

main subject

1 reference

Milen Minkov

1

1 reference

24 August 2017

publication date

1 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

75-86

1 reference

Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Chemotherapy of reticuloendotheliosis:Comparison of methotrexate plus prednisone vs. vincristine plus prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Histiocytosis X: Clinical trial of chlorambucil: A report from childrens cancer study group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Histiocytosis syndromes in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Current therapy for Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Outcome in children with pulmonary Langerhans cell Histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Pulmonary Langerhans cell histiocytosis: a variable disease in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Etoposide in recurrent childhood Langerhans' cell histiocytosis: an Italian cooperative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

A randomized trial of treatment for multisystem Langerhans' cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Oral methotrexate and alternate‐day prednisone for low‐risk langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Immunosuppressive treatment for chemotherapy-resistant multisystem Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

A phase II trial using thalidomide for Langerhans cell histiocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Drug therapy for the treatment of Langerhans cell histiocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Clofarabine in refractory Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Treatment of Langerhans cell histiocytosis with pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Bisphosphonate induces remission of refractory osteolysis in langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Controversies and new approaches to treatment of Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Langerhans cell histiocytosis: Current concepts and treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Biology of Langerhans cells and Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Expansion of regulatory T cells in patients with Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Langerhans cell histiocytosis: a pathologic combination of oncogenesis and immune dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Langerhans-cell histiocytosis 'insight into DC biology'.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Development of monocytes, macrophages, and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Serum levels of interleukin-1 receptor antagonist and tumor necrosis factor-alpha are elevated in children with Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Pattern and course of neurodegeneration in Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Neuropathology of CNS disease in Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

High dose immunoglobulin (IVIG) may reduce the incidence of Langerhans cell histiocytosis (LCH)-associated central nervous system involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538540-000000000-00000

Childhood histiocytosis X: clinical aspects and therapeutic approaches

21 January 2018

1 reference

12 December 2020

Histiocytosis X histogenetic arguments for a Langerhans cell origin

1 reference

12 December 2020

Use of indomethacin in Langerhans cell histiocytosis

1 reference

12 December 2020

Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X)

1 reference

12 December 2020

Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment

1 reference

12 December 2020

Historical perspectives of Langerhans cell histiocytosis

1 reference

12 December 2020

Therapy of histiocytosis X with vincristine, vinblastine, and cyclophosphamide. The Southwest Cancer Chemotherapy Study Group

1 reference

12 December 2020

Histiocytosis X; integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Schüller-Christian disease as related manifestations of a single nosologic entity

1 reference

12 December 2020

[Langerhans cell histiocytosis in childhood--results of the DAL-HX 83 study]

1 reference

12 December 2020

Reactivation and risk of sequelae in Langerhans cell histiocytosis

1 reference

12 December 2020

Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis

1 reference

12 December 2020

Use of cortisone and corticotropin (ACTH) in treatment of reticuloendotheliosis in children

1 reference

12 December 2020

Langerhans-cell histiocytosis: neoplasia or unbridled inflammation?

1 reference

12 December 2020

Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution.

1 reference

12 December 2020

Chlorambucil in histiocytosis X: a Southwest Oncology Group study

1 reference

12 December 2020

Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study

1 reference

12 December 2020

Brief communication: morphoproteomic analysis of osteolytic Langerhans cell histiocytosis with therapeutic implications.

1 reference

12 December 2020

Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis

1 reference

12 December 2020

1 reference

12 December 2020

A case of Letterer-Siwe disease treated with cortisone

1 reference

12 December 2020

Treatment of Langerhans cell histiocytosis--evolution and current approaches

1 reference

12 December 2020

Successful treatment of Langerhans'-cell histiocytosis with etanercept

1 reference

12 December 2020

Chemotherapy of histiocytosis-X.

1 reference

12 December 2020

Prednisolone, methotrexate, and 6-mercaptopurine in the treatment of histiocytosis X

1 reference

12 December 2020

Cladribine activity in adult langerhans-cell histiocytosis

1 reference

12 December 2020

The use of cortisone in the treatment of reticuloendotheliosis; cases from the pediatric service of the Valley Forge Army Hospital, Phoenixville, Pa

1 reference

12 December 2020

Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study

1 reference

12 December 2020

High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis

1 reference

12 December 2020

Evaluation of a MOPP-type regimen in histiocytosis X--a Southwest Oncology Group study

1 reference

12 December 2020

The role of BMT in childhood histiocytoses

1 reference

12 December 2020

Central nervous system disease in Langerhans cell histiocytosis

1 reference

12 December 2020

[Therapy of juvenile disseminated histiocytosis X. First results of a prospective study at the pediatric section of the Swiss Work Group for Clinical Cancer Research (SAKK)]

1 reference

12 December 2020

Lung involvement in Langerhans' cell histiocytosis: prevalence, clinical features, and outcome

1 reference

12 December 2020

Letterer-Siwe disease. Report of a case emphasizing effective corticosteroid therapy

1 reference

12 December 2020

Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society

1 reference

12 December 2020

10.2165/11538540-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1042461852

0 references

1 reference